Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M
Source: SeekingAlpha
2025-11-17 16:11:18 ET
More on Enanta Pharma
- Enanta Pharmaceuticals, Inc. (ENTA) RSVHR Study Results Presentation - Slideshow
- Enanta Pharmaceuticals, Inc. (ENTA) RSVHR Study Results Call (Transcript)
- Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change
- Enanta rises as J.P. Morgan starts at Overweight on RSV therapy
- Enanta upgraded to buy at Jefferies on promise of RSV antiviral zelicapavir
Read the full article on Seeking Alpha
For further details see:
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M
Enanta Pharmaceuticals Inc.
NASDAQ: ENTA
ENTA Trading
-4.37% G/L:
$13.47 Last:
42,804 Volume:
$13.86 Open:
ENTA Latest News
March 03, 2026 07:00:00 am
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
February 10, 2026 07:00:00 am
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
February 09, 2026 04:01:00 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
ENTA Stock Data
$400,455,604
24,201,447
4.66%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
